These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Correlation between the protein-bound iodine and butanol-extracted iodine in the blood serum of patients with diffuse toxic goiter during treatment with mercazolyl]. Okulov VB. Probl Endokrinol (Mosk); 1969; 15(4):5-8. PubMed ID: 4189655 [No Abstract] [Full Text] [Related]
6. [Dynamics of serum lipid changes in patients with diffuse toxic goiter during treatment with I-131]. Slukhaĭ IuF. Med Radiol (Mosk); 1967 May; 12(5):67-9. PubMed ID: 5633311 [No Abstract] [Full Text] [Related]
7. Treatment of toxic nodular and diffuse goitre with radioactive iodine. Late results and use of carbimazole. Viherkoski M, Lamberg BA, Hernberg CA, Niemi E. Acta Endocrinol (Copenh); 1970 May; 64(1):159-70. PubMed ID: 4195421 [No Abstract] [Full Text] [Related]
8. [The treatment of hyperthyroid syndromes. I. Specific therapy. (Clinico-statistical contribution)]. Donati GS, Guagliano G, Scotti-Foglieni C, Cortinovis R, Pedroni G, Molteni F. Chir Ital; 1967 Dec; 19(6):957-1106. PubMed ID: 4180460 [No Abstract] [Full Text] [Related]
9. Post-therapeutic thyroid reserve. Thyroid reserve in euthyroid patients after ablative therapy for diffuse toxic goiter. Prendergast JJ, Miller JM. Henry Ford Hosp Med J; 1970 Dec; 18(1):3-10. PubMed ID: 5467196 [No Abstract] [Full Text] [Related]
19. [Study of the degradation of labelled thyroxine in patients with hyperthyroidism treated with radioactive iodine]. Simonin R, Argémi B, Alland A, Paulin R, Bernard PJ. Ann Endocrinol (Paris); 1970 Jul 14; 31(3):363-6. PubMed ID: 4989456 [No Abstract] [Full Text] [Related]
20. [Use of thyrostatic preparations to reduce the radioresistance of toxic goiter during radioiodine treatment]. Livergant IuE, Suslina NG. Med Radiol (Mosk); 1968 Jul 14; 13(7):9-11. PubMed ID: 4190228 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]